Understanding the mechanisms and treatment options in cancer cachexia (original) (raw)

• Fearon, K. et al. Definition and classification of cancer cachexia: an international consensus. Lancet Oncol. 12, 489–495 (2011).
  Article PubMed Google Scholar
• Arends, J. et al. ESPEN Guidelines on Enteral Nutrition: non-surgical oncology. Clin. Nutr. 25, 245–259 (2006).
  Article CAS PubMed Google Scholar
• Kubrak, C. et al. Nutrition impact symptoms: key determinants of reduced dietary intake, weight loss, and reduced functional capacity of patients with head and neck cancer before treatment. Head Neck 32, 290–300 (2010).
  PubMed Google Scholar
• Simons, J. P. et al. Effects of medroxyprogesterone acetate on food intake, body composition, and resting energy expenditure in patients with advanced, nonhormone-sensitive cancer: a randomized, placebo-controlled trial. Cancer 82, 553–560 (1998).
  Article CAS PubMed Google Scholar
• Nixon, D. W. et al. Hyperalimentation of the cancer patient with protein-calorie undernutrition. Cancer Res. 41, 2038–2045 (1981).
  CAS PubMed Google Scholar
• Dodson, S. et al. Muscle wasting in cancer cachexia: clinical implications, diagnosis, and emerging treatment strategies. Annu. Rev. Med. 62, 265–279 (2011).
  Article CAS PubMed Google Scholar
• van Wetering, C. R. et al. Efficacy and costs of nutritional rehabilitation in muscle-wasted patients with chronic obstructive pulmonary disease in a community-based setting: a prespecified subgroup analysis of the INTERCOM trial. J. Am. Med. Dir. Assoc. 11, 179–187 (2010).
  Article PubMed Google Scholar
• Barratt, S. M., Smith, R. C., Kee, A. J., Mather, L. E. & Cousins, M. J. Multimodal analgesia and intravenous nutrition preserves total body protein following major upper gastrointestinal surgery. Reg. Anesth. Pain Med. 27, 15–22 (2002).
  Article PubMed Google Scholar
• Awad, S. et al. Marked changes in body composition following neoadjuvant chemotherapy for oesophagogastric cancer. Clin. Nutr. 31, 74–77 (2012).
  Article PubMed Google Scholar
• Smith, M. R. et al. Changes in body composition during androgen deprivation therapy for prostate cancer. J. Clin. Endocrinol. Metab. 87, 599–603 (2002).
  Article CAS PubMed Google Scholar
• Antoun, S. et al. Association of skeletal muscle wasting with treatment with sorafenib in patients with advanced renal cell carcinoma: results from a placebo-controlled study. J. Clin. Oncol. 28, 1054–1060 (2010).
  Article CAS PubMed Google Scholar
• Helbekkmo, N. et al. Chemotherapy and quality of life in NSCLC PS 2 patients. Acta Oncol. 48, 1019–1025 (2009).
  Article PubMed Google Scholar
• Kalantar-Zadeh, K. et al. Risk factor paradox in wasting diseases. Curr. Opin. Clin. Nutr. Metab. Care 10, 433–442 (2007).
  Article PubMed Google Scholar
• McAuley, P. A. & Blair, S. N. Obesity paradoxes. J. Sports Sci. 29, 773–782 (2011).
  Article PubMed Google Scholar
• Tan, B. H., Birdsell, L. A., Martin, L., Baracos, V. E. & Fearon, K. C. Sarcopenia in an overweight or obese patient is an adverse prognostic factor in pancreatic cancer. Clin. Cancer Res. 15, 6973–6979 (2009).
  Article CAS PubMed Google Scholar
• Prado, C. M. et al. Prevalence and clinical implications of sarcopenic obesity in patients with solid tumours of the respiratory and gastrointestinal tracts: a population-based study. Lancet Oncol. 9, 629–635 (2008).
  Article PubMed Google Scholar
• Martin, L. et al. Prognostic factors in patients with advanced cancer: use of the patient-generated subjective global assessment in survival prediction. J. Clin. Oncol. 28, 4376–4383 (2010).
  Article PubMed Google Scholar
• Pichard, C., Baracos, V. & Attaix, D. Would you buy a new tool to improve your practice? Curr. Opin. Clin. Nutr. Metab. Care 14, 221–222 (2011).
  Article PubMed Google Scholar
• Lieffers, J. R. et al. A viscerally-driven cachexia syndrome in patients with advanced colorectal cancer: contributions of organ and tumor mass to whole body energy demands. Am. J. Clin. Nutr. 89, 1173–1179 (2009).
  Article CAS PubMed PubMed Central Google Scholar
• Stephens, N. A. et al. Sexual dimorphism modulates the impact of cancer cachexia on lower limb muscle mass and function. Clin. Nutr. 31, 499–505 (2012).
  Article PubMed Google Scholar
• Costa, G. & Donaldson, S. S. Current concepts in cancer: effects of cancer and cancer treatment on the nutrition of the host. N. Engl. J. Med. 300, 1471–1474 (1979).
  Article CAS PubMed Google Scholar
• Andreyev, H. J., Norman, A. R., Oates, J. & Cunningham, D. Why do patients with weight loss have a worse outcome when undergoing chemotherapy for gastrointestinal malignancies? Eur. J. Cancer 34, 503–509 (1998).
  Article CAS PubMed Google Scholar
• Nitenberg, G. & Raynard, B. Nutritional support of the cancer patient: issues and dilemmas. Crit. Rev. Oncol. Hematol. 34, 137–168 (2000).
  Article CAS PubMed Google Scholar
• Stewart, G. D., Skipworth, R. J. & Fearon, K. C. Cancer cachexia and fatigue. Clin. Med. 6, 140–143 (2006).
  Article Google Scholar
• Watanabe, S. & Bruera, E. Anorexia and cachexia, asthenia, and lethargy. Hematol. Oncol. Clin. North Am. 10, 189–206 (1996).
  Article CAS PubMed Google Scholar
• Reid, J., McKenna, H., Fitzsimons, D. & McCance, T. Fighting over food: patient and family understanding of cancer cachexia. Oncol. Nurs. Forum 36, 439–445 (2009).
  Article PubMed Google Scholar
• Dewys, W. D. et al. Prognostic effect of weight loss prior to chemotherapy in cancer patients. Eastern Cooperative Oncology Group. Am. J. Med. 69, 491–497 (1980).
  Article CAS PubMed Google Scholar
• Ross, P. J. et al. Do patients with weight loss have a worse outcome when undergoing chemotherapy for lung cancer? Br. J. Cancer 90, 1905–1911 (2004).
  Article CAS PubMed PubMed Central Google Scholar
• Prado, C. M., Antoun, S., Sawyer, M. B. & Baracos, V. E. Two faces of drug therapy in cancer: drug-related lean tissue loss and its adverse consequences to survival and toxicity. Curr. Opin. Nutr. Metab. Care 14, 250–254 (2011).
  Article CAS Google Scholar
• Mir, O. et al. Sarcopenia predicts early dose-limiting toxicities and pharmacokinetics of sorafenib in patients with hepatocellular carcinoma. PLoS ONE 7, e37563 (2012).
  Article CAS PubMed PubMed Central Google Scholar
• Ardizzoni, A. et al. Cisplatin- versus carboplatin-based chemotherapy in first-line treatment of advanced non-small-cell lung cancer: an individual patient data meta-analysis. J. Natl Cancer Inst. 99, 847–857 (2007).
  Article CAS PubMed Google Scholar
• Straub, R. H., Cutolo, M., Buttgereit, F. & Pongratz, G. Energy regulation and neuroendocrine-immune control in chronic inflammatory diseases. J. Intern. Med. 267, 543–560 (2010).
  Article CAS PubMed Google Scholar
• Gibb, J., Audet, M. C., Hayley, S. & Anisman, H. Neurochemical and behavioral responses to inflammatory immune stressors. Front. Biosci. (Schol. Ed.) 1, 275–295 (2009).
  Article Google Scholar
• Myers, J. S. Proinflammatory cytokines and sickness behavior: implications for depression and cancer-related symptoms. Oncol. Nurs. Forum 35, 802–807 (2008).
  Article PubMed Google Scholar
• Fearon, K. C., Glass, D. J. & Guttridge, D. C. Cancer cachexia: mediators, signaling, and metabolic pathways. Cell Metab. 16, 153–166 (2012).
  Article CAS PubMed Google Scholar
• Braun, T. P. et al. Central nervous system inflammation induces muscle atrophy via activation of the hypothalamic-pituitary-adrenal axis. J. Exp. Med. 208, 2449–2463 (2011).
  Article CAS PubMed PubMed Central Google Scholar
• Tan, B. H. et al. P-selectin genotype is associated with the development of cancer cachexia. EMBO Mol. Med. 4, 462–471 (2012).
  Article CAS PubMed PubMed Central Google Scholar
• Das, S. K. et al. Adipose triglyceride lipase contributes to cancer-associated cachexia. Science 333, 233–238 (2011).
  Article CAS PubMed Google Scholar
• Kortebein, P., Ferrando, A., Lombeida, J., Wolfe, R. & Evans, W. J. Effect of 10 days of bed rest on skeletal muscle in healthy older adults. JAMA 297, 1772–1774 (2007).
  Article CAS PubMed Google Scholar
• Ferrando, A. A., Stuart, C. A., Sheffield-Moore, M. & Wolfe, R. R. Inactivity amplifies the catabolic response of skeletal muscle to cortisol. J. Clin. Endocrinol. Metab. 84, 3515–3521 (1999).
  CAS PubMed Google Scholar
• Murphy, R. A. et al. Aberrations in plasma phospholipid fatty acids in lung cancer patients. Lipids 47, 363–369 (2012).
  Article CAS PubMed Google Scholar
• Murphy, R. A. et al. Nutritional intervention with fish oil provides a benefit over standard of care for weight and skeletal muscle mass in patients with nonsmall cell lung cancer receiving chemotherapy. Cancer 117, 1775–1782 (2011).
  Article CAS PubMed Google Scholar
• Murphy, R. A. et al. Supplementation with fish oil increases first-line chemotherapy efficacy in patients with advanced nonsmall cell lung cancer. Cancer 117, 3774–3780 (2011).
  Article CAS PubMed Google Scholar
• Fakih, M. G. et al. Chemotherapy is linked to severe vitamin D deficiency in patients with colorectal cancer. Int. J. Colorectal Dis. 24, 219–224 (2009).
  Article PubMed Google Scholar
• Zeisel, S. H. & da Costa, K. A. Choline: an essential nutrient for public health. Nutr. Rev. 67, 615–623 (2009).
  Article PubMed Google Scholar
• Hasselgren, P. O. Glucocorticoids and muscle catabolism. Curr. Opin. Clin. Nutr. Metab. Care 2, 201–205 (1999).
  Article CAS PubMed Google Scholar
• Sheffield-Moore, M. et al. Androgen therapy induces muscle protein anabolism in older women. J. Clin. Endocrinol. Metab. 91, 3844–3849 (2006).
  Article CAS PubMed Google Scholar
• Gullett, N. P., Hebbar, G. & Ziegler, T. R. Update on clinical trials of growth factors and anabolic steroids in cachexia and wasting. Am. J. Clin. Nutr. 91, 1143S–1147S (2010).
  Article CAS PubMed PubMed Central Google Scholar
• Bodine, S. C. et al. Akt/mTOR pathway is a crucial regulator of skeletal muscle hypertrophy and can prevent muscle atrophy in vivo. Nat. Cell Biol. 3, 1014–1019 (2001).
  Article CAS PubMed Google Scholar
• Glass, D. J. PI3 kinase regulation of skeletal muscle hypertrophy and atrophy. Curr. Top. Microbiol. Immunol. 346, 267–278 (2010).
  CAS PubMed Google Scholar
• Trendelenburg, A. U. et al. Myostatin reduces Akt/TORC1/p70S6K signaling, inhibiting myoblast differentiation and myotube size. Am. J. Physiol. Cell Physiol. 296, C1258–1270 (2009).
  Article CAS PubMed Google Scholar
• Spiro, A., Baldwin, C., Patterson, A., Thomas, J. & Andreyev, H. J. The views and practice of oncologists towards nutritional support in patients receiving chemotherapy. Br. J. Cancer 95, 431–434 (2006).
  Article CAS PubMed PubMed Central Google Scholar
• Heyland, D. K. et al. Total parenteral nutrition in the surgical patient: a meta-analysis. Can. J. Surg. 44, 102–111 (2001).
  CAS PubMed Google Scholar
• Jatoi, A., Kumar, S., Sloan, J. A. & Nguyen, P. L. On appetite and its loss. J. Clin. Oncol. 18, 2930–2932 (2000).
  Article CAS PubMed Google Scholar
• Ries, A. L. Pulmonary rehabilitation: summary of an evidence-based guideline. Respir. Care 53, 1203–1207 (2008).
  PubMed Google Scholar
• de Gramont, A. et al. The evolution of adjuvant therapy in the treatment of early-stage colon cancer. Clin. Colorectal Cancer 10, 218–226 (2011).
  Article PubMed Google Scholar
• Vigano, A., Del Fabbro, E., Bruera, E. & Borod, E. The cachexia clinic: from staging to managing nutritional and functional problems in advanced cancer patients. Crit. Rev. Oncog. 17, 293–304 (2012).
  Article PubMed Google Scholar
• Manini, T. M. Energy expenditure and aging. Ageing Res. Rev. 9, 1–11 (2010).
  Article CAS PubMed Google Scholar
• Moses, A. W., Slater, C., Preston, T., Barber, M. D. & Fearon, K. C. Reduced total energy expenditure and physical activity in cachectic patients with pancreatic cancer can be modulated by an energy and protein dense oral supplement enriched with n-3 fatty acids. Br. J. Cancer 90, 996–1002 (2004).
  Article CAS PubMed PubMed Central Google Scholar
• Fearon, K. C. et al. Effect of a protein and energy dense N-3 fatty acid enriched oral supplement on loss of weight and lean tissue in cancer cachexia: a randomised double blind trial. Gut 52, 1479–1486 (2003).
  Article CAS PubMed PubMed Central Google Scholar
• Lundholm, K., Daneryd, P., Bosaeus, I., Korner, U. & Lindholm, E. Palliative nutritional intervention in addition to cyclooxygenase and erythropoietin treatment for patients with malignant disease: effects on survival, metabolism, and function. Cancer 100, 967–977 (2004).
  Article CAS Google Scholar
• Baldwin, C., Spiro, A., Ahern, R. & Emery, P. W. Oral nutritional interventions in malnourished patients with cancer: a systematic review and meta-analysis. J. Natl Cancer Inst. 7, 371–385 (2012).
  Article Google Scholar
• Ferriolli, E. et al. Physical activity monitoring: a responsive and meaningful patient-centered outcome for surgery, chemotherapy, or radiotherapy? J. Pain Symptom Manage. 43, 1025–1035 (2012).
  Article PubMed Google Scholar
• Lenk, K., Schuler, G. & Adams, V. Skeletal muscle wasting in cachexia and sarcopenia: molecular pathophysiology and impact of exercise training. J. Cachexia Sarcopenia Muscle 1, 9–21 (2010).
  Article PubMed PubMed Central Google Scholar
• Oldervoll, L. M. et al. Physical exercise for cancer patients with advanced disease: a randomized controlled trial. Oncologist 16, 1649–1657 (2011).
  Article PubMed PubMed Central Google Scholar
• Argilés, J. M., Busquets, S., López-Soriano, F. J., Costelli, P. & Penna, F. Are there any benefits of exercise training in cancer cachexia? J. Cachexia Sarcopenia Muscle 3, 73–76 (2012).
  Article PubMed PubMed Central Google Scholar
• Loprinzi, C. L. et al. Randomized comparison of megestrol acetate versus dexamethasone versus fluoxymesterone for the treatment of cancer anorexia/cachexia. J. Clin. Oncol. 17, 3299–3306 (1999).
  Article CAS PubMed Google Scholar
• Strasser, F. et al. Comparison of orally administered cannabis extract and δ-9-tetrahydrocannabinol in treating patients with cancer-related anorexia-cachexia syndrome: a multicenter, phase III, randomized, double-blind, placebo-controlled clinical trial from the Cannabis-In-Cachexia-Study-Group. J. Clin. Oncol. 24, 3394–3400 (2006).
  Article CAS PubMed Google Scholar
• Lundholm, K. et al. Anti-inflammatory treatment may prolong survival in undernourished patients with metastatic solid tumors. Cancer Res. 54, 5602–5606 (1994).
  CAS PubMed Google Scholar
• Lundholm, K., Daneryd, P., Körner, U., Hyltander, A. & Bosaeus, I. Evidence that long-term COX-treatment improves energy homeostasis and body composition in cancer patients with progressive cachexia. Int. J. Oncol. 24, 505–512 (2004).
  CAS PubMed Google Scholar
• Schmitz, G. & Ecker, J. The opposing effects of n-3 and n-6 fatty acids. Prog. Lipid Res. 47, 147–155 (2008).
  Article CAS PubMed Google Scholar
• Dewey, A., Baughan, C., Dean, T., Higgins, B. & Johnson, I. Eicosapentaenoic acid (EPA, an ω-3 fatty acid from fish oils) for the treatment of cancer cachexia. Cochrane Database of Systematic Reviews, Issue 1, Art. No.: CD004597. http://dx.doi.org/10.1002/14651858.CD004597.pub2.
• van der Meij, B. S. et al. Oral nutritional supplements containing (n-3) polyunsaturated fatty acids affect the nutritional status of patients with stage III non-small cell lung cancer during multimodality treatment. J. Nutr. 140, 1774–1780 (2010).
  Article CAS PubMed Google Scholar
• Noman, A. S. et al. Thalidomide inhibits lipopolysaccharide-induced tumor necrosis factor-α production via down-regulation of MyD88 expression. Innate Immun. 15, 33–41 (2009).
  Article CAS PubMed Google Scholar
• Bruera, E. et al. Thalidomide in patients with cachexia due to terminal cancer: preliminary report. Ann. Oncol. 10, 857–859 (1999).
  Article CAS PubMed Google Scholar
• Khan, Z. H. et al. Oesophageal cancer and cachexia: the effect of short-term treatment with thalidomide on weight loss and lean body mass. Aliment. Pharmacol. Ther. 17, 677–682 (2003).
  Article CAS PubMed Google Scholar
• Gordon, J. N. et al. Thalidomide in the treatment of cancer cachexia: a randomised placebo controlled trial. Gut 54, 540–545 (2005).
  Article CAS PubMed PubMed Central Google Scholar
• Moehler, T. Clinical experience with thalidomide and lenalidomide in multiple myeloma. Curr. Cancer Drug Targets 12, 372–390 (2012).
  Article CAS PubMed Google Scholar
• Heslin, M. J., Newman, E., Wolf, R. F., Pisters, P. W. & Brennan, M. F. Effect of systemic hyperinsulinemia in cancer patients. Cancer Res. 52, 3845–3850 (1992).
  CAS PubMed Google Scholar
• Newman, E., Heslin, M. J., Wolf, R. F., Pisters, P. W. & Brennan, M. F. The effect of insulin on glucose and protein metabolism in the forearm of cancer patients. Surg. Oncol. 1, 257–267 (1992).
  Article CAS PubMed Google Scholar
• Lundholm, K. et al. Insulin treatment in cancer cachexia: effects on survival, metabolism, and physical functioning. Clin. Cancer Res. 13, 2699–2706 (2007).
  Article CAS PubMed Google Scholar
• Neary, N. M. et al. Ghrelin increases energy intake in cancer patients with impaired appetite: acute, randomized, placebo-controlled trial. J. Clin. Endocrinol. Metab. 89, 2832–2836 (2004).
  Article CAS PubMed Google Scholar
• Garcia, J. M., Friend, J. & Allen, S. Therapeutic potential of anamorelin, a novel, oral ghrelin mimetic, in patients with cancer-related cachexia: a multicenter, randomized, double-blind, crossover, pilot study. Support. Care Cancer http://dx.doi.org/10.1007/s00520-012-1500-1.
• US National Library of Medicine. ClinicalTrials.gov [online], (2012).
• Dalton, J. T. et al. The selective androgen receptor modulator GTx-024 (enobosarm) improves lean body mass and physical function in healthy elderly men and postmenopausal women: results of a double-blind, placebo-controlled phase II trial. J. Cachexia Sarcopenia Muscle 2, 153–161 (2011).
  Article PubMed PubMed Central Google Scholar
• US National Library of Medicine. ClinicalTrials.gov [online], (2012).
• Zaki, M. H., Nemeth, J. A. & Trikha, M. CNTO 328, a monoclonal antibody to IL-6, inhibits human tumor-induced cachexia in nude mice. Int. J. Cancer 111, 592–595 (2004).
  Article CAS PubMed Google Scholar
• Bayliss, T. J., Smith, J. T., Schuster, M., Dragnev, K. H. & Rigas, J. R. A humanized anti-IL-6 antibody (ALD518) in non-small cell lung cancer. Expert Opin. Biol. Ther. 11, 1663–1668 (2011).
  Article CAS PubMed Google Scholar
• Prado, C. M. et al. Skeletal muscle anabolism is a side effect of therapy with the MEK inhibitor: selumetinib in patients with cholangiocarcinoma. Br. J. Cancer 106, 1583–1586 (2012).
  Article CAS PubMed PubMed Central Google Scholar
• Han, H. Q. & Mitch, W. E. Targeting the myostatin signaling pathway to treat muscle wasting diseases. Curr. Opin. Support Palliat. Care 5, 334–341 (2011).
  Article CAS PubMed PubMed Central Google Scholar
• Zhou, X. et al. Reversal of cancer cachexia and muscle wasting by ActRIIB antagonism leads to prolonged survival. Cell 142, 531–543 (2010).
  Article CAS PubMed Google Scholar
• Benny Klimek, M. E. et al. Acute inhibition of myostatin-family proteins preserves skeletal muscle in mouse models of cancer cachexia. Biochem. Biophys. Res. Commun. 391, 1548–1554 (2010).
  Article CAS PubMed Google Scholar
• US National Library of Medicine. ClinicalTrials.gov [online], (2012).
• US National Library of Medicine. ClinicalTrials.gov [online], (2012).
• American Dietetic Association. Oncology evidence-based nutrition practice guideline [online], (2007).
• August, D. A., Huhmann, M. B. & American Society for Parenteral and Enteral Nutrition (A. S. P. E. N.) Board of Directors. A. S. P. E. N. clinical guidelines: nutrition support therapy during adult anticancer treatment and in hematopoietic cell transplantation. JPEN J. Parenter. Enteral Nutr. 33, 472–500 (2009).
  Article PubMed Google Scholar
• Bauer, J. D. et al. Evidence based practice guidelines for the nutritional management of cancer cachexia. Nutr. Dietetics 63 (Suppl. s2), S3–S32 (2006).
  Article Google Scholar
• Bozzetti, F. et al. ESPEN Guidelines on Parenteral Nutrition: non-surgical oncology. Clin. Nutr. 28, 445–454 (2009).
  Article CAS PubMed Google Scholar
• Moore, F. A., Ziegler, T. R., Heyland, D. K., Marik, P. E. & Bistrian, B. R. Developing research programs in clinical and translational nutrition. JPEN J. Parenter. Enteral. Nutr. 34 (Suppl. 6), 97S–105S (2010).
  Article PubMed PubMed Central Google Scholar
• Commission on Cancer. Cancer Program Standards 2012: Ensuring Patient-Centered Care [online], (2012).
• OnkoZert [online], (2012).
• German Society of Hematology and Oncology [German, online], (2012).
• Boomsma, F. et al. Organisation of European Cancer Institutes Accreditation and Designation User Manual (eds Pierotti, M. A., van Harten W., Hummel, H. & Otter, R.) [online], (2011).
  Google Scholar
• Council of Europe Committee of Ministers. Resolution ResAP (2003)3 on food and nutritional care in hospitals [online], (2003).